Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Down 2.6% - Time to Sell?

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) fell 2.6% on Tuesday . The stock traded as low as $37.93 and last traded at $38.12. 114,650 shares changed hands during trading, a decline of 72% from the average session volume of 414,313 shares. The stock had previously closed at $39.12.

Wall Street Analyst Weigh In

AMPH has been the subject of several recent analyst reports. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an "equal weight" rating and a $55.00 price objective for the company. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $60.33.

Amphastar Pharmaceuticals Trading Down 2.2 %

The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 12.76, a PEG ratio of 0.87 and a beta of 0.78. The business's 50-day simple moving average is $46.26 and its two-hundred day simple moving average is $44.56.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 7,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the sale, the executive vice president now owns 118,469 shares of the company's stock, valued at $5,262,392.98. This trade represents a 5.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Yakob Liawatidewi sold 5,214 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $271,388.70. Following the completion of the transaction, the executive vice president now owns 74,938 shares of the company's stock, valued at $3,900,522.90. This represents a 6.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 41,533 shares of company stock worth $1,987,482 over the last ninety days. Company insiders own 27.10% of the company's stock.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Large investors have recently bought and sold shares of the business. Aurora Investment Counsel boosted its position in shares of Amphastar Pharmaceuticals by 0.4% during the 3rd quarter. Aurora Investment Counsel now owns 54,698 shares of the company's stock worth $2,654,000 after acquiring an additional 232 shares in the last quarter. GAMMA Investing LLC increased its stake in Amphastar Pharmaceuticals by 70.0% in the third quarter. GAMMA Investing LLC now owns 663 shares of the company's stock valued at $32,000 after purchasing an additional 273 shares during the last quarter. Crossmark Global Holdings Inc. raised its holdings in Amphastar Pharmaceuticals by 2.5% during the second quarter. Crossmark Global Holdings Inc. now owns 11,300 shares of the company's stock worth $452,000 after purchasing an additional 275 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Amphastar Pharmaceuticals by 20.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company's stock worth $85,000 after buying an additional 301 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Amphastar Pharmaceuticals by 53.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock valued at $56,000 after buying an additional 398 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company's stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.